Immuneering Corp (IMRX): Price and Financial Metrics


Immuneering Corp (IMRX): $4.62

0.29 (+6.70%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMRX Stock Price Chart Interactive Chart >

Price chart for IMRX

IMRX Price/Volume Stats

Current price $4.62 52-week high $33.99
Prev. close $4.33 52-week low $3.74
Day low $4.07 Volume 39,300
Day high $4.68 Avg. volume 143,554
50-day MA $5.91 Dividend yield N/A
200-day MA $16.55 Market Cap 121.90M

Immuneering Corp (IMRX) Company Bio


Immuneering Corporation provides genetic, genomic, and proteomic data analysis services for pharmaceutical companies to generate biological insights that enhance the clinical and commercial success of medicines. The company was incorporated in 2008 and is based in Cambridge, Massachusetts.


IMRX Latest News Stream


Event/Time News Detail
Loading, please wait...

IMRX Latest Social Stream


Loading social stream, please wait...

View Full IMRX Social Stream

Latest IMRX News From Around the Web

Below are the latest news stories about Immuneering Corp that investors may wish to consider to help them evaluate IMRX as an investment opportunity.

Immuneering Announces Participation in March Investor Conferences

Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cellsCAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that management will participate in two March

Yahoo | February 24, 2022

Immuneering Corp (IMRX) Investor Presentation - Slideshow

No summary available.

Seeking Alpha | February 11, 2022

Should You Buy Immuneering (IMRX) Ahead of Earnings?

Immuneering (IMRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Yahoo | February 7, 2022

What Is The Ownership Structure Like For Immuneering Corporation (NASDAQ:IMRX)?

The big shareholder groups in Immuneering Corporation ( NASDAQ:IMRX ) have power over the company. Large companies...

Yahoo | January 31, 2022

Immuneering Announces Participation in Upcoming Investor Conferences

Highlighting proprietary pipeline of oncology drug candidates that spare healthy normal cells by modulating signaling dynamics to focus therapeutic efficacy against tumor cellsCAMBRIDGE, Mass., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that are designed to uniquely disrupt cellular signaling dynamics, today announced that Ben Zeskind, Ph.D., Co-Founder, Presiden

Yahoo | January 24, 2022

Read More 'IMRX' Stories Here

IMRX Price Returns

1-mo -7.04%
3-mo -38.15%
6-mo -79.58%
1-year N/A
3-year N/A
5-year N/A
YTD -71.43%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.5374 seconds.